Sue Egstrand to lead Karo Healthcare
Stockholm-based Karo Healthcare has appointed Sue Egstrand as CEO, effective January 1, 2027. She will lead the consumer healthcare company’s next phase of growth, with the goal of becoming one of Europe’s top five consumer healthcare players.
“Karo has built a strong European consumer healthcare platform, with significant opportunities for further growth. Sue brings the right combination of consumer healthcare experience and international leadership expertise to build on Karo’s achievements to date, strengthen its commercial momentum, and scale the business across markets,” says Hans Arstad, Partner at KKR and Chair of the Board of Karo Healthcare.
Sue Egstrand
Egstrand has held senior leadership roles at Pfizer, GSK, and Reckitt. At Reckitt she was Senior Vice President, Europe Health, where she led the regional strategy and delivered strong top- and bottom-line growth. She comes most recently from Dechra, a private equity-backed animal health company, where she was President, Europe and International, and Chief Commercial Officer.
“I am excited to join Karo at an important stage in the company’s development. Karo has built a strong portfolio of trusted brands, an international presence, and significant opportunities ahead,” says Sue Egstrand.
Egstrand succeeds Christoffer Lorenzen. Karo’s products, which include Lamisil, E45, Pevaryl, and Paracet, are sold in more than 90 countries, and the company has about 600 employees.
Published: November 16, 2026
